Table VII.
Efficacy of CAPOX in comparison to FUFOX in first-line chemotherapy in patients aged <70 and ≥70 years of agea.
| Age <70 years (n=330) | Age ≥70 years (n=138) | FUFOX ≥70 years (n=63) | CAPOX ≥70 years (n=75) | |
|---|---|---|---|---|
| Median time to disease progression (months) | 7.5 | 7.6 | 7.9 | 7.6 |
| Median overall survival (months) | 18.8 | 14.4 | 14.4 | 14.2 |
| Response (%) | ||||
| CR + PR | 52 | 49 | 54 | 46 |
| CR | 5 | 2 | 2 | 3 |
| PR | 47 | 47 | 52 | 43 |
| SD | 26 | 23 | 19 | 27 |
a
Based on the findings of Arkenau et al (11).
CR, complete response; PR, partial response; CR + PR, objective response; SD, stable disease.